Caris Highlights the Value of Whole Exome and Transcriptome Sequencing for Cancer Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy CAI?
Source: Newsfilter
- Importance of Cancer Testing: Caris Life Sciences emphasizes the critical role of DPYD testing during Colorectal Cancer Awareness Month, noting that colorectal cancer remains one of the most commonly diagnosed cancers in the U.S., with rising incidence among younger adults, highlighting the urgent need for early detection and personalized treatment.
- FDA Safety Label Update: The FDA has updated safety labeling for capecitabine and 5-FU to advise genetic variant testing for DPYD prior to treatment, aiming to reduce the risk of severe toxicity and ensure patient safety during chemotherapy.
- Efficiency through Technology Integration: By incorporating DPYD reporting into its blood-based Whole Exome and Whole Transcriptome Sequencing, Caris enables clinicians to assess tumor biomarkers and inherited variants from a single blood draw, streamlining the decision-making process before treatment.
- Future of Personalized Treatment: Caris President David Spetzler emphasizes that DPYD testing provides crucial information for clinical decision-making, helping physicians develop safer treatment plans for patients who may be candidates for fluoropyrimidine-based therapies, thus advancing the field of precision medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 16.850
Low
30.00
Averages
36.17
High
40.00
Current: 16.850
Low
30.00
Averages
36.17
High
40.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Caris Life Sciences Introduces New AI Signatures for Cancer Risk Assessment
- New AI Signatures Launched: Caris Life Sciences has announced the addition of two new Caris AI Insights™ signatures that assess the risk of brain metastases in breast and lung cancer patients, bringing the total to seven proprietary insights, thereby enhancing clinical decision-making precision.
- Data-Driven Decision Support: These new signatures are based on a large dataset of 12,994 NSCLC cases and 3,371 breast cancer cases with matched survival outcomes, generating personalized predictive scores using patients' Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) data to better identify high-risk patients.
- Clinical Application Prospects: By providing Kaplan-Meier curve visualizations, Caris's AI signatures enable clinicians to intuitively assess the likelihood of brain metastasis development in patients, facilitating a shift from passive surveillance to more proactive monitoring, thus improving patient care quality.
- FDA-Approved Innovation: Caris received FDA approval for MI Cancer Seek in November 2024, marking it as the first tissue-based assay with simultaneous WES and WTS capabilities, underscoring the company's leadership in precision oncology and advancing personalized medicine efforts.
See More
Caris Life Sciences Introduces New AI Signatures for Cancer Risk Assessment
- New AI Signatures Launched: Caris Life Sciences has introduced two new Caris AI Insights™ signatures that assess the risk of brain metastases in breast and lung cancer patients, increasing the total number of proprietary AI insights to seven, thereby enhancing decision-making support for physicians and patients.
- Clinical Decision Support: These new signatures are based on a dataset of 12,994 non-small cell lung cancer and 3,371 breast cancer cases with matched survival outcomes, generating personalized predictive scores that enable clinicians to shift from passive surveillance to more proactive monitoring strategies, ultimately improving patient prognosis.
- FDA-Approved Innovation: Caris received FDA approval in November 2024 for MI Cancer Seek, the first tissue-based assay that simultaneously utilizes Whole Exome and Whole Transcriptome Sequencing, marking a significant advancement in precision oncology and enhancing the company's competitive position in the market.
- Global Collaboration Network: Ongoing studies within the Caris Precision Oncology Alliance® (POA®) will highlight how Caris AI Insights can predict brain metastasis risk, further advancing precision medicine and biomarker-driven research, solidifying the company's leadership in global cancer research.
See More
Caris Life Sciences to Present Six Studies at AACR Annual Meeting
- Research Presentation: Caris Life Sciences will showcase six studies at the 2026 American Association for Cancer Research Annual Meeting, leveraging its multimodal database that integrates Whole Exome Sequencing, Whole Transcriptome Sequencing, and clinical data to advance precision oncology and enhance patient treatment outcomes.
- Multimodal Data Utilization: The studies focus on breast, prostate, lung, and colorectal cancers, revealing clinically relevant patterns through deep molecular analysis, demonstrating the transformative potential of multimodal molecular data to accelerate discovery and improve patient outcomes.
- Strengthened Collaborative Network: The collaboration with leading cancer centers underscores the power of large-scale real-world molecular evidence, enhancing the credibility of the research and providing critical clinical insights for future treatment decisions.
- Commitment to Technological Innovation: Caris is dedicated to developing innovative precision medicine solutions through advanced AI and machine learning technologies, showcasing its leadership in transforming healthcare and further solidifying its competitive advantage in the industry.
See More
Caris Life Sciences to Present Six Studies at AACR Annual Meeting
- Research Presentation: Caris Life Sciences will showcase six studies at the 2026 American Association for Cancer Research Annual Meeting, focusing on breast, prostate, lung, and colorectal cancers, reflecting the company's leadership in precision oncology and potentially advancing related treatment options.
- Data Integration Advantage: These studies leverage Caris' multimodal database, integrating Whole Exome Sequencing, Whole Transcriptome Sequencing, and clinical data to generate clinically meaningful insights, underscoring the importance of large-scale molecular evidence in accelerating discovery and improving patient outcomes.
- Clinical Decision Support: By combining deep genomic profiling with real-world clinical evidence, Caris' research directly informs treatment decisions, which may accelerate the development of more effective therapies, thereby enhancing patient treatment outcomes.
- Industry Impact: This presentation not only highlights Caris' innovative capabilities in precision medicine but also has the potential to attract more partners and investors, further solidifying its market position in the biotechnology industry.
See More
Caris Highlights Importance of Whole Exome and Transcriptome Sequencing for Cancer Patients
- Importance of Cancer Testing: Caris Life Sciences emphasizes the critical role of DPYD testing during Colorectal Cancer Awareness Month, highlighting that colorectal cancer remains one of the most commonly diagnosed cancers in the U.S., with rising incidence among younger adults necessitating earlier detection and personalized care.
- FDA Safety Label Update: The FDA has updated safety labeling for capecitabine and 5-FU to advise testing for DPYD gene variants prior to treatment, aiming to reduce the risk of severe toxicity from these therapies and ensure patient safety.
- Efficiency Through Technology Integration: Caris incorporates DPYD reporting into its blood-based Whole Exome and Whole Transcriptome Sequencing, allowing clinicians to assess tumor biomarkers and inherited variants from a single blood draw, thereby streamlining care and enhancing actionable information availability.
- Future of Personalized Treatment: Caris President David Spetzler emphasizes that DPYD testing provides crucial information for clinical decision-making, and as the oncology community advances toward more individualized care, increasing awareness of pharmacogenomic factors will help improve patient treatment experiences.
See More
Caris Highlights the Value of Whole Exome and Transcriptome Sequencing for Cancer Patients
- Importance of Cancer Testing: Caris Life Sciences emphasizes the critical role of DPYD testing during Colorectal Cancer Awareness Month, noting that colorectal cancer remains one of the most commonly diagnosed cancers in the U.S., with rising incidence among younger adults, highlighting the urgent need for early detection and personalized treatment.
- FDA Safety Label Update: The FDA has updated safety labeling for capecitabine and 5-FU to advise genetic variant testing for DPYD prior to treatment, aiming to reduce the risk of severe toxicity and ensure patient safety during chemotherapy.
- Efficiency through Technology Integration: By incorporating DPYD reporting into its blood-based Whole Exome and Whole Transcriptome Sequencing, Caris enables clinicians to assess tumor biomarkers and inherited variants from a single blood draw, streamlining the decision-making process before treatment.
- Future of Personalized Treatment: Caris President David Spetzler emphasizes that DPYD testing provides crucial information for clinical decision-making, helping physicians develop safer treatment plans for patients who may be candidates for fluoropyrimidine-based therapies, thus advancing the field of precision medicine.
See More
Caris Life Sciences Introduces New AI Signatures for Cancer Risk Assessment
- New AI Signatures Launched: Caris Life Sciences has announced the addition of two new Caris AI Insights™ signatures that assess the risk of brain metastases in breast and lung cancer patients, bringing the total to seven proprietary insights, thereby enhancing clinical decision-making precision.
- Data-Driven Decision Support: These new signatures are based on a large dataset of 12,994 NSCLC cases and 3,371 breast cancer cases with matched survival outcomes, generating personalized predictive scores using patients' Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) data to better identify high-risk patients.
- Clinical Application Prospects: By providing Kaplan-Meier curve visualizations, Caris's AI signatures enable clinicians to intuitively assess the likelihood of brain metastasis development in patients, facilitating a shift from passive surveillance to more proactive monitoring, thus improving patient care quality.
- FDA-Approved Innovation: Caris received FDA approval for MI Cancer Seek in November 2024, marking it as the first tissue-based assay with simultaneous WES and WTS capabilities, underscoring the company's leadership in precision oncology and advancing personalized medicine efforts.
See More
Caris Life Sciences Introduces New AI Signatures for Cancer Risk Assessment
- New AI Signatures Launched: Caris Life Sciences has introduced two new Caris AI Insights™ signatures that assess the risk of brain metastases in breast and lung cancer patients, increasing the total number of proprietary AI insights to seven, thereby enhancing decision-making support for physicians and patients.
- Clinical Decision Support: These new signatures are based on a dataset of 12,994 non-small cell lung cancer and 3,371 breast cancer cases with matched survival outcomes, generating personalized predictive scores that enable clinicians to shift from passive surveillance to more proactive monitoring strategies, ultimately improving patient prognosis.
- FDA-Approved Innovation: Caris received FDA approval in November 2024 for MI Cancer Seek, the first tissue-based assay that simultaneously utilizes Whole Exome and Whole Transcriptome Sequencing, marking a significant advancement in precision oncology and enhancing the company's competitive position in the market.
- Global Collaboration Network: Ongoing studies within the Caris Precision Oncology Alliance® (POA®) will highlight how Caris AI Insights can predict brain metastasis risk, further advancing precision medicine and biomarker-driven research, solidifying the company's leadership in global cancer research.
See More
Caris Life Sciences to Present Six Studies at AACR Annual Meeting
- Research Presentation: Caris Life Sciences will showcase six studies at the 2026 American Association for Cancer Research Annual Meeting, leveraging its multimodal database that integrates Whole Exome Sequencing, Whole Transcriptome Sequencing, and clinical data to advance precision oncology and enhance patient treatment outcomes.
- Multimodal Data Utilization: The studies focus on breast, prostate, lung, and colorectal cancers, revealing clinically relevant patterns through deep molecular analysis, demonstrating the transformative potential of multimodal molecular data to accelerate discovery and improve patient outcomes.
- Strengthened Collaborative Network: The collaboration with leading cancer centers underscores the power of large-scale real-world molecular evidence, enhancing the credibility of the research and providing critical clinical insights for future treatment decisions.
- Commitment to Technological Innovation: Caris is dedicated to developing innovative precision medicine solutions through advanced AI and machine learning technologies, showcasing its leadership in transforming healthcare and further solidifying its competitive advantage in the industry.
See More
Caris Life Sciences to Present Six Studies at AACR Annual Meeting
- Research Presentation: Caris Life Sciences will showcase six studies at the 2026 American Association for Cancer Research Annual Meeting, focusing on breast, prostate, lung, and colorectal cancers, reflecting the company's leadership in precision oncology and potentially advancing related treatment options.
- Data Integration Advantage: These studies leverage Caris' multimodal database, integrating Whole Exome Sequencing, Whole Transcriptome Sequencing, and clinical data to generate clinically meaningful insights, underscoring the importance of large-scale molecular evidence in accelerating discovery and improving patient outcomes.
- Clinical Decision Support: By combining deep genomic profiling with real-world clinical evidence, Caris' research directly informs treatment decisions, which may accelerate the development of more effective therapies, thereby enhancing patient treatment outcomes.
- Industry Impact: This presentation not only highlights Caris' innovative capabilities in precision medicine but also has the potential to attract more partners and investors, further solidifying its market position in the biotechnology industry.
See More
Caris Highlights Importance of Whole Exome and Transcriptome Sequencing for Cancer Patients
- Importance of Cancer Testing: Caris Life Sciences emphasizes the critical role of DPYD testing during Colorectal Cancer Awareness Month, highlighting that colorectal cancer remains one of the most commonly diagnosed cancers in the U.S., with rising incidence among younger adults necessitating earlier detection and personalized care.
- FDA Safety Label Update: The FDA has updated safety labeling for capecitabine and 5-FU to advise testing for DPYD gene variants prior to treatment, aiming to reduce the risk of severe toxicity from these therapies and ensure patient safety.
- Efficiency Through Technology Integration: Caris incorporates DPYD reporting into its blood-based Whole Exome and Whole Transcriptome Sequencing, allowing clinicians to assess tumor biomarkers and inherited variants from a single blood draw, thereby streamlining care and enhancing actionable information availability.
- Future of Personalized Treatment: Caris President David Spetzler emphasizes that DPYD testing provides crucial information for clinical decision-making, and as the oncology community advances toward more individualized care, increasing awareness of pharmacogenomic factors will help improve patient treatment experiences.
See More
Caris Highlights the Value of Whole Exome and Transcriptome Sequencing for Cancer Patients
- Importance of Cancer Testing: Caris Life Sciences emphasizes the critical role of DPYD testing during Colorectal Cancer Awareness Month, noting that colorectal cancer remains one of the most commonly diagnosed cancers in the U.S., with rising incidence among younger adults, highlighting the urgent need for early detection and personalized treatment.
- FDA Safety Label Update: The FDA has updated safety labeling for capecitabine and 5-FU to advise genetic variant testing for DPYD prior to treatment, aiming to reduce the risk of severe toxicity and ensure patient safety during chemotherapy.
- Efficiency through Technology Integration: By incorporating DPYD reporting into its blood-based Whole Exome and Whole Transcriptome Sequencing, Caris enables clinicians to assess tumor biomarkers and inherited variants from a single blood draw, streamlining the decision-making process before treatment.
- Future of Personalized Treatment: Caris President David Spetzler emphasizes that DPYD testing provides crucial information for clinical decision-making, helping physicians develop safer treatment plans for patients who may be candidates for fluoropyrimidine-based therapies, thus advancing the field of precision medicine.
See More
